Indication

Prostate cancer - hormone-sensitive

RAG rating

Amber initiation

Document type

Decision document

Place

Hertfordshire and West Essex ICB

Output type

Pharmacy / Prescribing

Relugolix (Orgovyx)

HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)

Relugolix for treating hormone-sensitive prostate cancer

AMBER INITIATION

Recommended for initiation by specialists, ongoing prescribing in primary care in line with prescribing support document.

Name generic (trade) Relugolix (Orgovyx®)

What it is Non-peptide GnRH receptor antagonist

Indication Recommended an option for treating prostate cancer in adults:

·       with advanced hormone-sensitive prostate cancer

·       alongside radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate cancer

·       as neoadjuvant treatment before radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate cancer.

Date decision last revised June 2025

Decision status Final

NICE / SMC Guidance NICE TA995 recommended for restricted use.

HWE APC recommendation:

Relugolix is recommended, within its marketing authorisation, as an option for treating hormone-sensitive prostate cancer in line with the recommendations in line with NICE TA995 and locally agreed prescribing support document.

AMBER INITIATION STATUS:

Recommended for initiation by specialists with continuation in Primary Care in line with prescribing support document

NICE TA995 recommendations:

Relugolix is recommended, within its marketing authorisation, as an option for treating prostate cancer in adults:

·       with advanced hormone-sensitive prostate cancer

·       alongside radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate cancer

·       as neoadjuvant treatment before radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate cancer.